Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Whitepaper
Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications
Using biologically sourced material for biotherapeutics has achieved significant success in recent years, with transformative innovations throughout the entire cell line development (CLD) process. Automation, clone selection, scalability, and digitization have all contributed to increased agility, precision, and throughput while meeting regulatory compliance requirements.
Explore this whitepaper detailing what the cell line development challenges are and how they can be addressed with advanced technologies. Covering areas such as:
- How to prevent clone instability
- Achieving acceptable protein expression
- Allowing for non-fragmented, multi-copy gene cassette integration
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications